TY - JOUR
T1 - Use of Ketamine in Patients with Multifactorial Neuropathic Pain
T2 - A Systematic Review and Meta-Analysis
AU - Bruna-Mejias, Alejandro
AU - Baeza, Vicente
AU - Gamboa, Javiera
AU - Baez Flores, Belen
AU - San Martin, Jessica
AU - Astorga, Constanza
AU - Leyton, Javiera
AU - Nova-Baeza, Pablo
AU - Orellana-Donoso, Mathias
AU - Suazo-Santibañez, Alejandra
AU - Becerra-Farfán, Alvaro
AU - Oyanedel-Amaro, Gustavo
AU - Valenzuela-Fuenzalida, Juan Jose
N1 - Publisher Copyright:
© 2024 by the authors.
PY - 2024/9
Y1 - 2024/9
N2 - Neuropathic pain (NP) is a heterogeneous group of conditions characterized by the experience of a number of sensory disturbances including pain, burning sensations, paroxysms of stabbing pain, dysesthesias, allodynia, and hyperalgesia. The above-mentioned sensations may occur in a specific dermatome area or other delimited region of the body. The objective of this review was to analyze the evidence for ketamine in multifactorial neuropathic pain. The research group systematically searched the databases MEDLINE (via PubMed), EMBASE, SCOPUS, the Cochrane Central Register of Controlled Trials, the Cumulative Index to Nursing and Allied Health Literature (Cinahl), and the Web of Science. The findings of this review show that different forms of low doses of ketamine (LDK) do not present statistically significant changes for any of the scales included. In this study, the total symptom score [standardized mean difference (SMD) = −3.59, confidence interval (CI) = −4.16 to −3.02, and p < 0.00001], neuropathy impairment score (SMD = −1.42, CI = −3.68 to 0.84, and p = 0.22), and neuropathy symptom checklist (SMD = −0.09, CI = −0.15 to −0.02, and p = 0.01) were taken into account. For finality compared to the use of a placebo, the findings suggest that LDK does not exhibit significant differences in terms of pain reduction and functionality. Moreover, no specific dosages are identified to support the use of LDK in the reduction in NP.
AB - Neuropathic pain (NP) is a heterogeneous group of conditions characterized by the experience of a number of sensory disturbances including pain, burning sensations, paroxysms of stabbing pain, dysesthesias, allodynia, and hyperalgesia. The above-mentioned sensations may occur in a specific dermatome area or other delimited region of the body. The objective of this review was to analyze the evidence for ketamine in multifactorial neuropathic pain. The research group systematically searched the databases MEDLINE (via PubMed), EMBASE, SCOPUS, the Cochrane Central Register of Controlled Trials, the Cumulative Index to Nursing and Allied Health Literature (Cinahl), and the Web of Science. The findings of this review show that different forms of low doses of ketamine (LDK) do not present statistically significant changes for any of the scales included. In this study, the total symptom score [standardized mean difference (SMD) = −3.59, confidence interval (CI) = −4.16 to −3.02, and p < 0.00001], neuropathy impairment score (SMD = −1.42, CI = −3.68 to 0.84, and p = 0.22), and neuropathy symptom checklist (SMD = −0.09, CI = −0.15 to −0.02, and p = 0.01) were taken into account. For finality compared to the use of a placebo, the findings suggest that LDK does not exhibit significant differences in terms of pain reduction and functionality. Moreover, no specific dosages are identified to support the use of LDK in the reduction in NP.
KW - ketamine
KW - neuropathic pain
KW - pharmacology
KW - polyneuropathy
UR - http://www.scopus.com/inward/record.url?scp=85205081067&partnerID=8YFLogxK
U2 - 10.3390/ph17091165
DO - 10.3390/ph17091165
M3 - Review article
AN - SCOPUS:85205081067
SN - 1424-8247
VL - 17
JO - Pharmaceuticals
JF - Pharmaceuticals
IS - 9
M1 - 1165
ER -